Wuhan Fuxing Bio-Pharmaceutical Co., Ltd. is a holding subsidiary of China's top 500 private enterprises Fuxing Group, which is a modern high-tech enterprise integrating drug research and development, production and sales on the basis of the acquisition of the original "Hanchuan Pharmaceutical Factory" in July 2001. Over the years, the company adheres to the concept of "committed to people's health and longevity, improve the quality of human life", and strictly implements the concept of "starting from prevention to control product quality, and creating safety and effectiveness with standard details; With the quality policy of continuous improvement to ensure quality leadership and do high-quality drugs to serve people's health, we ensure the safety and effectiveness of drugs for the general public. The company has been rated as China's pharmaceutical quality and integrity "double excellent" enterprises, "China's pharmaceutical growth Top 50 enterprises", Hubei Province "specialized special new" small giant enterprise, "Hubei Province pillar industry segmentation field hidden champion cultivation" enterprises.
The company covers an area of 160,000 square meters, and has 275 employees, of which 29 are undergraduates or above and 71 are medical-related professional and technical personnel. The company has 116 approval documents for Chinese and Western pharmaceutical preparations, and 54 varieties are included in the national essential drugs list; The company has more than 130 sets of advanced testing instruments and production equipment.
The company's production scope: large capacity injection (plastic bottles, glass bottles, vertical polypropylene infusion bags, multi-layer co-extruded infusion soft bags), small capacity injection, hard capsules, granules, tablets and other modern high-speed production lines.
Business scope: Licensed items: drug production, drug commissioned production, drug import and export (according to law to be approved by the relevant departments before the approval of business activities), the specific business projects in the relevant departments of the approval documents or license shall be subject to. General projects: production of traditional Chinese medicine extracts, manufacturing of medical packaging materials, technical services, technology development, technical consultation, technical exchange, technology transfer, technology promotion (in addition to licensing business, can independently operate according to law not prohibited or restricted by laws and regulations projects).
New product development partners: Since its establishment, the company has always adhered to the strategy of "innovation to increase efficiency, improve development", and established long-term scientific research cooperation relations with a number of scientific research institutes such as Hubei Institute of Pharmaceutical Industry, Fangda Pharmaceutical, Beijing Xinkaiyuan, Qingdao Aureithen, laying a solid foundation for the development of the company.
Aggressive technical team: The company has three invention patents such as "new preparation method of Banxia Hewei Keli Chinese patent medicine" and eight utility model patents such as "air valve system for purifying air conditioning unit". The company's technical team was rated as "Hubei Key Industry technology innovation Team" and "Xiaogan Key industry Technology innovation Team". The company's independent research and development of "Banxia Hewei Keli" was awarded "National Key New products" by four ministries, including the Ministry of Science and Technology and the Ministry of Commerce, and was selected as the national medical insurance catalog and the exclusive national manufacturer in 2019.
160000
㎡
116
+
275
130
+
